Bundibugyo ebolavirus
Coverage of Bundibugyo ebolavirus in the Nexus archive.
- Congo-Kinshasa: Unicef and Gavi Launch Call to Manufacturers in Support of Accelerated Access to Bundibugyo Ebolavirus Vaccines
UNICEF and Gavi launched a Request for Expression of Interest to gather information from vaccine developers and manufacturers about plans to create a Bundibugyo Ebolavirus vaccine. Gavi has committed $40 million to support accelerated access to the vaccine.
- STAT+: Global coalition to fast-track three vaccines targeting Ebola outbreak with $62 million in funding
A global coalition is fast-tracking three vaccines targeting the Bundibugyo ebolavirus, with $62 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI). The current outbreak in the Democratic Republic of Congo lacks a licensed vaccine, as Merck’s Ervebo only targets the Zaire ebolavirus.
- Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo
CEPI has committed $50 million to Moderna for preclinical development and Phase 1 testing of an mRNA-based vaccine against Bundibugyo ebolavirus (BDBV). The funding aims to accelerate efforts to address an outbreak in the Democratic Republic of the Congo, leveraging Moderna's mRNA platform used during the COVID-19 pandemic.